ChemicalBook > Product Catalog >API >Drugs Influencing Immune Function >Immunosuppressive drugs >Rapamycin

Rapamycin

Rapamycin Suppliers list
Company Name:Dalian Meilun Biotech Co., Ltd.  Gold
Tel:0411-66771943;0411-66771942
Email:sales@meilune.com
Company Name:Fujian Kerui Pharmaceutical Co., Ltd.  Gold
Tel:15960103919
Email:fjkerui@gmail.com
Company Name:Shanghai Arbor Chemical Co., Ltd.  Gold
Tel:+86-21-60451683 50171870 +86-15021268886
Email:sales@arborchemical.com
Company Name:Chongqing Chemieliva Pharmaceutical Co., Ltd.  Gold
Tel:+86 (23) 6777-0219
Email:jessica.hu@chemieliva.com
Company Name:Wuhan Dahua Weiye Pharmaceutical Chemical Co., Ltd.  Gold
Tel:027-59887161
Email:2846469424@qq.com
Rapamycin Basic information
Immunosuppressant Discovery History Targeted Cancer Therapy Drugs Side Effects Uses
Product Name:Rapamycin
Synonyms:AY 22989;23,27-EPOXY-3H-PYRIDO(2,1-C)(1,4)OXAAZACYCLOHENTRIACONTINE;NSC-226080;RAPA;RAPAMUNE;RAPAMYCIN;RAPAMYCIN, STREPTOMYCES HYGROSCOPICUS;RPM
CAS:53123-88-9
MF:C51H79NO13
MW:914.18
EINECS:262-640-9
Product Categories:Active Pharmaceutical Ingredients;Immunosuppressant;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Cytokine signaling;Signalling;API;Chiral Reagents;Heterocycles;Inhibitor;VIVACTIL;antibiotic
Mol File:53123-88-9.mol
Rapamycin Structure
Rapamycin Chemical Properties
mp 183-185°C
Fp 87 °C
storage temp. -20°C
Sensitive Moisture Sensitive/Light Sensitive/Hygroscopic
CAS DataBase Reference53123-88-9(CAS DataBase Reference)
Safety Information
Hazard Codes Xi,Xn,F
Risk Statements 36/38-36-20/21/22-11
Safety Statements 22-24/25-37/39-26-36/37-16
RTECS VE6250000
Hazardous Substances Data53123-88-9(Hazardous Substances Data)
MSDS Information
ProviderLanguage
Sirolimus English
Rapamycin Usage And Synthesis
ImmunosuppressantRapamycin (RAPA) is a new type of large ring lactone immunosuppressant. It is white solid crystal, melting point of 183-185 oC, lipophilic, soluble in methanol, ethanol, acetone, chloroform and other organic solvents, very slightly soluble in water, hardly soluble in ether. It was developed in the early 1970s, initially was as low toxicity antifungal drugs, and was found immunosuppressive in 1977. From 1989, RAPA was as a new drug for the treatment of organ transplantation rejection in trial, and from animal experiments and clinical application effects, it is of good curative effects, low toxicity and no new immunosuppressant nephrotoxicity. Now rapamycin is frequently as maintaining immunity drug for transplant organs (especially kidney transplant), to slow down the immune rejection of the organ in transplant surgery, however, scientists recently discovered another purpose: it can be used in the treatment of alzheimer's disease (senile dementia). To their interest, the main composition of rapamycin exists in Easter island isolated bacteria in the soil, and recent experiments show that the material used in the experimental rats can have ability to restore the memorization defects on the body.
Rapamycin is a large ring lactone antibiotic, it has the similar composition with Zyprexa (FK506), but has very different mechanism of immunosuppression. FK506 suppressor T lymphocyte proliferation from G0 to G1 phase, whereas RAPA blocks signal transduction through different cells, and the process of T cells and other cells from G1 phase to S phase. Compared with FK506, RAPA blocks the signal pathways of T lymphocytes and B lymphocytes depended on calcium or not.
Medical researchers from University of Chicago combined commercially available rapamycin oral tablets with grapefruit juice in the treatment of melanoma (a kind of malignant tumor disease common in European and American people), which could greatly improve the anticancer effect of other chemotherapy drugs, thereby prolong the survival time of patients. Studies have shown that rapamycin is easy to decompose by enzyme on entering the digestive tract, and the grapefruit juice contains a large number of coumarin and furan, which can inhibit the digestive enzymes from damaging the effects of rapamycin, so it can improve the bioavailability of rapamycin. It is said that the earliest Dutch doctor had found: grapefruit juice have a function to improve the oral absorption effect of sandimmune, which now is applied to the formulation of rapamycin by the European and American doctors.
Discovery HistoryRapamycin (sirolimus) is a kind of secondary metabolite produced by the soil streptomyces secretion firstly found in Chile Easter island soil in 1975, and its chemical structure belongs to "triene large ring lactone class" compounds. Due to the low rapamycin fermentation yield and complicated extraction process, until 1999, the product was developed and appeared in the market by American household chemicals company, and then gone public in a dozen countries in Europe and the United States. The U.S. food and drug administration (FDA) approved indications of rapamycin is not antibiotics but "immunosuppressant. This is because rapamycin showed a strong immunosuppressive effect in clinical trials, and can replace ring spore which has a clinical history more than 30 years. And compared with ring spore, the oral dose of rapamycin is smaller (only take 2 ~ 3 mg each time), anti-rejection effect is stronger, and less side effects. So since rapamycin listed, it was quickly used as common oral immune inhibitors for transplants in the world.
Targeted Cancer Therapy DrugsIn recent years, studies found that as an intracellular kinase, the pathway abnormality of rapamycin target protein (mTOR) may induce many diseases. Rapamycin as mTOR’s targeted inhibitor, can treat the tumors closely related to the pathway including kidney cancer, lymphoma, lung cancer, liver cancer, breast cancer, neuroendocrine carcinoma and gastric cancer, etc. Especially for LAM (lymphatic fibroid disease) and TSC tuberous sclerosis - the treatment effect of the two kinds of rare diseases is more apparent, and to some extent LAM and TSC can be considered as tumor diseases.
Side EffectsRapamycin (RAPA) has similar side effects to FK506. Found in a large number of clinical trials, its side effects are dose dependent, and reversible, therapeutic dose RAPA have not been found to have obvious renal toxicity, no gingival hyperplasia. Main side effects include headache, nausea, dizziness, nose bleeding, joint pain. Laboratory abnormalities include: thrombocytopenia, leukopenia, lower hemoglobin, high blood triglycerides, high cholesterol, high blood sugar, elevated liver enzymes (SGOT, SGPT), lactate dehydrogenase, low potassium, low magnesium levels, etc. Recently there have been reports that RAPA can produce eyelid edema, and the cause of the low level of plasma phosphate was thought to be RAPA immunosuppressive therapy on the basis of the extended phosphate from the elimination of the transplanted kidney. Like other immunosuppressants, RAPA increases the chance of infection, there are reports on pneumonia increasing, but the other opportunistic infection has no obvious difference between CsA.
UsesUsed as immunosuppressant.
This information is edited by ChemicalBook Xiao Nan.
Chemical PropertiesWhite to Off-White Solid
UsageA specific mTOR inhibitor with an IC50 of 0.1 nM.
Usageantidepressant
Usageimmunosuppressant, antineoplastic; rapamycin
UsageRapamycin is a triene macrolide discovered in 1995 as a metabolite of Streptomyces hygroscopicus found in a soil obtained on Rapi Nui (Easter Island). Rapamycin displayed potent and selective antifungal activity, notably against Candida albicans. Interest in the metabolite waned until the structural relationship to the potent immunosuppressant fujimycin (Antibiotic FK506) was recognised in the mid-1980s. This recognition led to the re-discovery of rapamycin as a highly selective antitumour and immunosuppressant. Rapamycin inhibits the activity of the protein, mTOR (mammalian target of rapamycin) which functions in a signalling pathway to promote tumour growth. Rapamycin binds to a receptor protein (FKBP12). The rapamycin/FKB12 complex then binds to mTOR and prevents interaction of mTOR with target proteins in this signalling pathway.
UsageDDP-4 inhibitor type 2 diabetes therapeutic
UsageRapamycin is a triene macrolide discovered in 1974 as a metabolite of Streptomyces hygroscopicus found in a soil obtained on Rapa Nui (Easter Island). Rapamycin displayed potent and selective antifungal activity, notably against Candida albicans. Interest in the metabolite waned until the structural relationship to the potent immunosuppressant fujimycin (Antibiotic FK506) was recognised in the mid-1980s. This recognition led to the re-discovery of rapamycin as a highly selective antitumor and immunosuppressant. Rapamycin inhibits the activity of the protein, mTOR (mammalian target of rapamycin) which functions in a signalling pathway to promote tumor growth. Rapamycin binds to a receptor protein (FKBP12). The rapamycin/FKB12 complex then binds to mTOR and prevents interaction of mTOR with target proteins in this signalling pathway.
UsageLabelled Rapamycin. A triene macrolide antibiotic isolated from Streptomyces hygroscopicus. Name derived from the native word for Easter Island, Rapa?Nui. Used as an immunosuppressant; antirestenotic. This compound contains aproximately 2% d0.;Labeled Sir
Biological ActivityAntifungal and immunosuppressant. Specific inhibitor of mTOR (mammalian target of Rapamycin). Complexes with FKBP-12 and binds mTOR inhibiting its activity. Inhibits interleukin-2-induced phosphorylation and activation of p70 S6 kinase.
Rapamycin Preparation Products And Raw materials
Tag:Rapamycin(53123-88-9) Related Product Information
NA Mycophenolate mofetil Azithromycin POLYOXIN B Zopiclone NA SECO RAPAMYCIN SODIUM SALT RAPAMYCIN [3H(G)] mTOR, phosphorylated (pSer2481) (mTAb1, Mammalian Target of Rapamycin, FRAP, RAFT) (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)rapamycin mTOR, phosphorylated (Ser2448) (mTAb1, Mammalian Target of Rapamycin, FRAP, RAFT) ANTI-MAMMALIAN TARGET OF RAPAMYCIN,ANTI-FKBP-12 RAPAMYCIN ASSOCIATED PROTEIN 42-O-(2-Hydroxyethyl-d4)rapamycin RAPAMYCIN ASSOCIATED PROTEIN FRAP2 FRAGMENT BIOTINYL/AMIDE rapamycin tris-epoxide metabolite mTOR, aa2433-2450 (mTAb1, Mammalian Target of Rapamycin, FRAP, RAFT) RAPAMYCIN [32 METHOXY-3H] Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate